ILUSTRO

NCT03505320 📎

Regimen

Experimental: zolbetuximab monotherapy (Cohort 1A), zolbetuximab + mFOLFOX6 (Cohort 2), or zolbetuximab + pembrolizumab (Cohort 3A)

Population

CLDN18.2-positive advanced G/GEJ adenocarcinoma across late-line (1A, 3A) and first-line (Cohort 2) cohorts

Key finding

1L+chemo mPFS 17.8 mo, ORR 71.4%; monotherapy 3L+ ORR 0%, mPFS 1.54 mo; zolbetuximab+pembro 3L+ ORR 0%, mPFS 2.96 mo

Source: PMID 37490286

Timeline